



Practitioner's Docket No. **MPI00-557P1RM**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Chiang, Lillian Wei-Ming		
Application No.:	10/047,855	Group No.:	1642
Filed:	January 15, 2002	Examiner:	Holleran, Anne L.
For:	NARC10 AND NARC16, PROGRAMMED CELL DEATH-ASSOCIATED MOLECULES AND USES THEREOF		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (3 pages – in duplicate);
 - b. Amendment and Response to Restriction Requirement (4 pages);
 - c. Transmittal of Supplemental Information Disclosure Statement (2 pages);
 - d. Supplemental Information Disclosure Statement (2 pages);
 - e. Form PTO/SB/08A and Form PTO/SB/08B (substitute for Form PTO-1449) (2 pages);
 - f. Copies of References cited in Supplemental Information Disclosure Statement (Citation Nos. A4-A7, B4-B7);
 - g. Authorization to Act in a Representative Capacity (2 pages);
 - h. Statement of Limited Recognition under 37CFR §11.9(b) for Mario Cloutier (1 page) and;
 - i. Return Postcard.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: June 6, 2005

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

STATUS

2. Applicant is other than a small entity.

PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a one month extension:

Fee: \$120.00

Extension fee due with this request \$120.00

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)			(Col. 2)		(Col. 3)	OTHER THAN A SMALL ENTITY		
Claims Remaining After Amendment			Highest No. Previously Paid For		Present Extra	Rate	Addit. Fee	
Total	10	Minus	23	=	0	\$50.00	=	\$0.00
Indep.	2	Minus	6	=	0	\$200.00	=	\$0.00
Multiple Dependent Claims	no		no			\$360.00	=	\$0.00
						Total Addit. Fee	\$0.00	

Total additional fee for claims required \$0.00

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$120.00 (which includes the \$120.00 extension fee). A duplicate of this transmittal is attached.

FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.
7. Correspondence Address
Direct all future correspondence to:

Customer Number 30405
OR
Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

June 6, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By Mario Cloutier
Mario Cloutier
Limited Recognition Under 37 C.F.R. §11.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 29, 2006



Harry I. Moatz
Director of Enrollment and Discipline